Several observational studies to help improve knowledge of Huntington's and speed treatment development are now enrolling patients in the U.S.| Huntington's Disease News
Early care planning helps Huntington's patients and families cope as the disease progresses, speakers at the HDSA annual convention said.| Huntington's Disease News
US neurologists are optimistic about the potential for a new Huntington's disease treatment - preferably a gene therapy - per a market survey.| Huntington's Disease News
Ingrezza's effects on Huntington's-associated chorea appear stronger over time, according to an analysis of the Phase 3 KINECT-HD trial.| Huntington's Disease News
Ingrezza has been associated with sustained reductions in Huntington's chorea, regardless of concurrent antipsychotic medication use.| Huntington's Disease News
Treatment with valbenazine significantly lessened chorea motor symptoms in Huntington’s patients; an FDA submission is planned for 2022.| Huntington's Disease News
The once-daily oral therapy Ingrezza, from Neurocrine, has now been approved in the U.S. to treat chorea in adults with Huntington’s disease.| Huntington's Disease News
Columnist Carlos Briceño is devastated to realize how much the symptoms of Huntington's are beginning to affect his wife, Jill.| Huntington's Disease News
The outlook for the Huntington's community has never been brighter, Louise Vetter, president and CEO of the HDSA, said at the organization's annual convention.| Huntington's Disease News
An oral granule formulation of Ingrezza, called Ingrezza Sprinkle, has been granted FDA approval for treating Huntington's-associated chorea.| Huntington's Disease News
Ingrezza is an oral medication approved in the U.S. for chorea, or the involuntary, jerky movements that characterize Huntington’s disease.| Huntington's Disease News
Ingrezza Sprinkle is a formulation of oral Ingrezza that's designed to be easier to swallow, with capsule's granules sprinkled on soft foods.| Huntington's Disease News